| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Matthew L Sherman last filed a Form 4 in June 2023, as Director at PULM. Matthew L Sherman's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 20,000 shares of PULM. Net of sales, the PULM filings show accumulation of 20,000 shares.
Matthew L Sherman has 12 Form 4 filings on record from September 2016 to June 2023, across 2 companies: Director at Palvella Therapeutics (PVLA), 2018–2023; Director at Pulmatrix (PULM), 2016–2019.
The 14 reported transactions were 11 option or other derivative awards and 3 open-market purchases.
There are no priced open-market purchases or sales on record, so none of these filings shows a decision to buy or sell shares in the market.
Shares as reported in the last Form 4 for each company; the most recent is from June 2023. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Apr 3, 2018 | PULM Pulmatrix, Inc. | Director | Buy | 20,000 | $0.00 | - | New |